VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. According to the company, the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications.
Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego. The BiTAC (Bispecific T-cell Adaptor Construct) platforms represent a novel approach to cancer therapy. The BiTAC-ADC platform combines bispecific antibodies with antibody-drug conjugates (ADCs) to achieve tumor-restricted activation, potentially reducing systemic toxicity. The BiTAC-TCE platform focuses on T-cell engagers designed to recruit immune cells to tumors. VERAXA believes these platforms could address significant unmet needs in oncology by offering more precise and effective treatment options.
VERAXA Biotech, founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), is building an engine for the discovery and development of next-generation antibody-based therapeutics. The company's pipeline includes bispecific T cell engagers, bispecific ADCs, and other innovative formats. For more information on the full press release, visit https://ibn.fm/r8zEz. Updates on the company are available in the newsroom at https://ibn.fm/VRXA.
The news comes as the biotech industry gathers for one of its largest annual events, where partnerships and collaborations often shape the future of drug development. By showcasing its platforms at BIO, VERAXA aims to attract potential partners to advance its technologies into clinical trials and ultimately to patients. The company's focus on solid tumors is particularly noteworthy, as these cancers remain difficult to treat with existing immunotherapies due to the immunosuppressive tumor microenvironment. VERAXA's BiTAC platforms could offer new mechanisms to overcome these challenges, potentially improving outcomes for patients with limited options.
